Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Indian Journal of Gastroenterology
Erschienen in: Indian Journal of Gastroenterology 5/2019

05.12.2019 | Original Article

Indian consensus on gastroesophageal reflux disease in adults: A position statement of the Indian Society of Gastroenterology

verfasst von: Shobna J. Bhatia, Govind K. Makharia, Philip Abraham, Naresh Bhat, Ajay Kumar, D. Nageshwar Reddy, Uday C. Ghoshal, Vineet Ahuja, G. Venkat Rao, Krishnadas Devadas, Amit K. Dutta, Abhinav Jain, Saurabh Kedia, Rohit Dama, Rakesh Kalapala, Jose Filipe Alvares, Sunil Dadhich, Vinod Kumar Dixit, Mahesh Kumar Goenka, B. D. Goswami, Sanjeev K. Issar, Venkatakrishnan Leelakrishnan, Mohandas K. Mallath, Philip Mathew, Praveen Mathew, Subhashchandra Nandwani, Cannanore Ganesh Pai, Lorance Peter, A. V. Siva Prasad, Devinder Singh, Jaswinder Singh Sodhi, Randhir Sud, Jayanthi Venkataraman, Vandana Midha, Amol Bapaye, Usha Dutta, Ajay K. Jain, Rakesh Kochhar, Amarender S. Puri, Shivram Prasad Singh, Lalit Shimpi, Ajit Sood, Rajkumar T. Wadhwa

Erschienen in: Indian Journal of Gastroenterology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

The Indian Society of Gastroenterology developed this evidence-based practice guideline for management of gastroesophageal reflux disease (GERD) in adults. A modified Delphi process was used to develop this consensus containing 58 statements, which were generated by electronic voting iteration as well as face-to-face meeting and review of the supporting literature primarily from India. These statements include 10 on epidemiology, 8 on clinical presentation, 10 on investigations, 23 on treatment (including medical, endoscopic, and surgical modalities), and 7 on complications of GERD. When the proportion of those who voted either to accept completely or with minor reservation was 80% or higher, the statement was regarded as accepted. The prevalence of GERD in India ranges from 7.6% to 30%, being  < 10% in most population studies, and higher in cohort studies. The dietary factors associated with GERD include use of spices and non-vegetarian food. Helicobacter pylori is thought to have a negative relation with GERD; H. pylori negative patients have higher grade of symptoms of GERD and esophagitis. Less than 10% of GERD patients in India have erosive esophagitis. In patients with occasional or mild symptoms, antacids and histamine H2 receptor blockers (H2RAs) may be used, and proton pump inhibitors (PPI) should be used in patients with frequent or severe symptoms. Prokinetics have limited proven role in management of GERD.
Literatur
1.
Bhatia SJ, Reddy DN, Ghoshal UC, et al. Epidemiology and symptom profile of gastroesophageal reflux in the Indian population: report of the Indian Society of Gastroenterology Task Force. Indian J Gastroenterol. 2011;30:118–27.PubMed
2.
Chowdhury SD, George G, Ramakrishna K, et al. Prevalence and factors associated with gastroesophageal reflux disease in southern India: a community-based study. Indian J Gastroenterol. 2019;38:77–82.PubMed
3.
Wang HY, Leena KB, Plymoth A, et al. Prevalence of gastro-esophageal reflux disease and its risk factors in a community-based population in southern India. BMC Gastroenterol. 2016;16:36.PubMedPubMedCentral
4.
Kumar S, Sharma S, Norboo T, et al. Population based study to assess prevalence and risk factors of gastroesophageal reflux disease in a high altitude area. Indian J Gastroenterol. 2011;30:135–43.PubMed
5.
Amarapurkar AD, Vora IM, Dhawan PS. Barrett’s esophagus. Indian J Pathol Microbiol. 1998;41:431–5.PubMed
6.
7.
Periodic health examination: 2. 1984 update. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J. 1984;130:1278–85.
8.
Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus G. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–20.PubMed
9.
Sharma PK, Ahuja V, Madan K, Gupta S, Raizada A, Sharma MP. Prevalence, severity, and risk factors of symptomatic gastroesophageal reflux disease among employees of a large hospital in northern India. Indian J Gastroenterol. 2011;30:128–34.PubMed
10.
Bhalaghuru CM, Vijaya S, Jayanthi V. Symptomatic gastroesophageal reflux amongst hospital personnel in South India. Indian J Med Sci. 2011;65:355–9.PubMed
11.
Bhatia S, Gupta D, Vennalaganti P. Epidemiology of gastroesophageal reflux in Asia. The rise of acid reflux in Asia. J Neurogastroenterol Motil. 2017;17:14–27.
12.
El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63:871–80.PubMed
13.
Eusebi LH, Ratnakumaran R, Yuan Y, Solaymani-Dodaran M, Bazzoli F, Ford AC. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018;67:430–40.PubMed
14.
Chang P, Friedenberg F. Obesity and GERD. Gastroenterol Clin N Am. 2014;43:161–73.
15.
Vaishnav B, Bamanikar A, Maske P, Reddy A, Dasgupta S. Gastroesophageal reflux disease and its association with body mass index: clinical and endoscopic study. J Clin Diagn Res. 2017;11:OC01–4.PubMedPubMedCentral
16.
National Nutrition Monitoring Bureau, NNMB Technical Report No. 26, Diet and nutritional status of rural population, prevalence of hypertension & diabetes among adults and infant & young child feeding practices, Report of Third Repeat Survey National Institute of Nutrition, Indian Council of Medical Research, Hyderabad, India – 2012. Available at: http://​nnmbindia.​org. Accessed 08 May 2019.
17.
Corley DA, Kubo A. Body mass index and gastroesophageal reflux disease: a systematic review and meta-analysis. Am J Gastroenterol. 2006;101:2619–28.PubMed
18.
Këlliçi I, Kraja B. Smoking, alcohol, physical activity and gastroesophageal reflux disease: a literature review and the Albanian experience. Albanian Medical Journal. 2014;4:91–8.
19.
Sethi S, Richter JE. Diet and gastroesophageal reflux disease: role in pathogenesis and management. Curr Opin Gastroenterol. 2017;33:107–11.PubMed
20.
Arivan R, Deepanjali S. Prevalence and risk factors of gastro-esophageal reflux disease among undergraduate medical students from a southern Indian medical school: a cross-sectional study. BMC Res Notes. 2018;11:448.
21.
Kim J, Oh SW, Myung SK, et al. Association between coffee intake and gastroesophageal reflux disease: a meta-analysis. Dis Esophagus. 2014;27:311–7.PubMed
22.
Ghoshal UC, Chourasia D. Gastroesophageal reflux disease and Helicobacter pylori: what may be the relationship? J Neurogastroenterol Motil. 2010;16:243–50.PubMedPubMedCentral
23.
Goh KL. Gastroesophageal reflux disease in Asia: a historical perspective and present challenges. J Gastroenterol Hepatol. 2011;26 Suppl 1:2–10.PubMed
24.
Peng S, Cui Y, Xiao YL, et al. Prevalence of erosive esophagitis and Barrett’s esophagus in the adult Chinese population. Endoscopy. 2009;41:1011–7.PubMed
25.
Nam SY, Choi IJ, Ryu KH, Kim BC, Kim CG, Nam BH. Effect of Helicobacter pylori infection and its eradication on reflux esophagitis and reflux symptoms. Am J Gastroenterol. 2010;105:2153–62.PubMed
26.
Gerson LB, Kahrilas PJ, Fass R. Insights into gastroesophageal reflux disease-associated dyspeptic symptoms. Clin Gastroenterol Hepatol. 2011;9:824–33.PubMed
27.
Ghoshal UC, Abraham P, Bhatt C, et al. Epidemiological and clinical profile of irritable bowel syndrome in India: report of the Indian Society of Gastroenterology Task Force. Indian J Gastroenterol. 2008;27:22–8.PubMed
28.
Lovell RM, Ford AC. Prevalence of gastro-esophageal reflux-type symptoms in individuals with irritable bowel syndrome in the community: a meta-analysis. Am J Gastroenterol. 2012;107:1793–801.PubMed
29.
Fock KM, Talley N, Goh KL, et al. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett’s oesophagus. Gut. 2016;65:1402–15.PubMed
30.
Richter JE, Rubenstein JH. Presentation and epidemiology of gastroesophageal reflux disease. Gastroenterology. 2018;154:267–76.PubMed
31.
Baruah B, Kumar T, Das P, et al. Prevalence of eosinophilic esophagitis in patients with gastroesophageal reflux symptoms: a cross-sectional study from a tertiary care hospital in North India. Indian J Gastroenterol. 2017;36:353–60.PubMed
32.
33.
Quigley EM, Hungin AP. Review article: quality-of-life issues in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005;22 Suppl 1:41–7.PubMed
34.
Becher A, El-Serag H. Systematic review: The association between symptomatic response to proton pump inhibitors and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2011;34:618–27.PubMed
35.
Bitnar P, Stovicek J, Andel R, et al. Leg raise increases pressure in lower and upper esophageal sphincter among patients with gastroesophageal reflux disease. J Bodyw Mov Ther. 2016;20:518–24.PubMed
36.
Sodhi JS, Zargar SA, Javid G, et al. Effect of bending exercise on gastroesophageal reflux in symptomatic patients. Indian J Gastroenterol. 2008;27:227–31.PubMed
37.
Khan BA, Sodhi JS, Zargar SA, et al. Effect of bed head elevation during sleep in symptomatic patients of nocturnal gastroesophageal reflux. J Gastroenterol Hepatol. 2012;27:1078–82.PubMed
38.
Allampati S, Lopez R, Thota PN, Ray M, Birgisson S, Gabbard SL. Use of a positional therapy device significantly improves nocturnal gastroesophageal reflux symptoms. Dis Esophagus. 2017;30:1–7.PubMed
39.
Hamilton JW, Boisen RJ, Yamamoto DT, Wagner JL, Reichelderfer M. Sleeping on a wedge diminishes exposure of the esophagus to refluxed acid. Dig Dis Sci. 1988;33:518–22.PubMed
40.
Pollmann H, Zillessen E, Pohl J, et al. Effect of elevated head position in bed in therapy of gastroesophageal reflux. Z Gastroenterol. 1996;34 Suppl 2:93–9.PubMed
41.
van Herwaarden MA, Katzka DA, Smout AJ, Samsom M, Gideon M, Castell DO. Effect of different recumbent positions on postprandial gastroesophageal reflux in normal subjects. Am J Gastroenterol. 2000;95:2731–6.PubMed
42.
Khoury RM, Camacho-Lobato L, Katz PO, Mohiuddin MA, Castell DO. Influence of spontaneous sleep positions on nighttime recumbent reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol. 1999;94:2069–73.PubMed
43.
Orr WC. Sleep and gastroesophageal reflux: what are the risks? Am J Med. 2003;115:109–3S.
44.
Shoenut JP, Yamashiro Y, Orr WC, Kerr P, Micflikier AB, Kryger MH. Effect of severe gastroesophageal reflux on sleep stage in patients with a peristaltic esophagus. Dig Dis Sci. 1996;41:372–6.PubMed
45.
Freidin N, Fisher MJ, Taylor W, et al. Sleep and nocturnal acid reflux in normal subjects and patients with reflux oesophagitis. Gut. 1991;32:1275–9.PubMedPubMedCentral
46.
Ramu B, Mohan P, Rajasekaran MS, Jayanthi V. Prevalence and risk factors for gastroesophageal reflux in pregnancy. Indian J Gastroenterol. 2011;30:144–7.PubMed
47.
Gaddam S, Maddur H, Wani S, et al. Risk factors for nocturnal reflux in a large GERD cohort. J Clin Gastroenterol. 2011;45:764–8.PubMed
48.
Ghoshal UC, Chourasia D, Tripathi S, Misra A, Singh K. Relationship of severity of gastroesophageal reflux disease with gastric acid secretory profile and esophageal acid exposure during nocturnal acid breakthrough: a study using 24-h dual-channel pH-metry. Scand J Gastroenterol. 2008;43:654–61.PubMed
49.
Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308–28.PubMed
50.
Niu XP, Yu BP, Wang YD, et al. Risk factors for proton pump inhibitor refractoriness in Chinese patients with non-erosive reflux disease. World J Gastroenterol. 2013;19:3124–9.PubMedPubMedCentral
51.
Lee ES, Kim N, Lee SH, et al. Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux disease. Aliment Pharmacol Ther. 2009;30:154–64.PubMed
52.
Bytzer P, van Zanten SV, Mattsson H, et al. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis—a post hoc analysis of 5796 patients. Aliment Pharmacol Ther. 2012;36:635–43.PubMed
53.
Amarasiri DL, Pathmeswaran A, de Silva HJ, Ranasinha CD. Response of the airways and autonomic nervous system to acid perfusion of the esophagus in patients with asthma: a laboratory study. BMC Pulm Med. 2013;13:33.PubMedPubMedCentral
54.
Stein MR. Possible mechanisms of influence of esophageal acid on airway hyperresponsiveness. Am J Med. 2003;115 Suppl 3A:55S–9S.PubMed
55.
Schan CA, Harding SM, Haile JM, Bradley LA, Richter JE. Gastroesophageal reflux-induced bronchoconstriction. An intraesophageal acid infusion study using state-of-the-art technology. Chest. 1994;106:731–7.PubMed
56.
Ates F, Vaezi MF. Insight into the relationship between gastroesophageal reflux disease and asthma. Gastroenterol Hepatol. 2014;10:729–36.
57.
Sandur V, Murugesh M, Banait V, et al. Prevalence of gastro-esophageal reflux disease in patients with difficult to control asthma and effect of proton pump inhibitor therapy on asthma symptoms, reflux symptoms, pulmonary function and requirement for asthma medications. J Postgrad Med. 2014;60:282–6.PubMed
58.
Charles S, Johnson P, Padmavathi R, Rajagopalan, Subhashini AS, Kumar AP. The prevalence of the gastro oesophageal reflux disease in asthmatics. J Clin Diagn Res. 2011;5:711–3.
59.
Rameschandra S, Acharya V, Kunal VT, Ramkrishna A, Acharya P. Prevalence and spectrum of gastro esophageal reflux disease in bronchial asthma. J Clin Diagn Res. 2015;9:OC11–4.PubMedPubMedCentral
60.
Smith J, Woodcock A, Houghton L. New developments in reflux-associated cough. Lung. 2010;188 Suppl 1:S81–6.PubMed
61.
Woodcock A, Young EC, Smith JA. New insights in cough. Br Med Bull. 2010;96:61–73.PubMed
62.
Smith J, Decalmer S, Kelsall A, et al. Acoustic cough-reflux associations in chronic cough: potential triggers and mechanisms. Gastroenterology. 2010;139:754–62.PubMed
63.
Pore R, Biswas S, Das S. Prevailing practices for the management of dry cough in India: a questionnaire based survey. J Assoc Physicians India. 2016;64:48–54.PubMed
64.
Kahrilas PJ, Smith JA, Dicpinigaitis PV. A causal relationship between cough and gastroesophageal reflux disease (GERD) has been established: a pro/con debate. Lung. 2014;192:39–46.PubMed
65.
Ford CN. Evaluation and management of laryngopharyngeal reflux. JAMA. 2005;294:1534–40.PubMed
66.
Maldhure S, Chandrasekharan R, Dutta AK, Chacko A, Kurien M. Role of pH monitoring in laryngopharyngeal reflux patients with voice disorders. Iran J Otorhinolaryngol. 2016;28:377–83.PubMedPubMedCentral
67.
Belafsky PC, Postma GN, Koufman JA. The validity and reliability of the reflux finding score (RFS). Laryngoscope. 2001;111:1313–7.PubMed
68.
Hicks DM, Ours TM, Abelson TI, Vaezi MF, Richter JE. The prevalence of hypopharynx findings associated with gastroesophageal reflux in normal volunteers. J Voice. 2002;16:564–79.PubMed
69.
Campagnolo AM, Priston J, Thoen RH, Medeiros T, Assunção AR. Laryngopharyngeal reflux: diagnosis, treatment, and latest research. Int Arch Otorhinolaryngol. 2014;18:184–91.PubMed
70.
Fass R, Achem SR. Noncardiac chest pain: epidemiology, natural course and pathogenesis. J Neurogastroenterol Motil. 2011;17:110–23.PubMedPubMedCentral
71.
Stahl WG, Beton RR, Johnson CS, Brown CL, Waring JP. Diagnosis and treatment of patients with gastroesophageal reflux and non cardiac chest pain. South Med J. 1994;87:739–42.PubMed
72.
Jain M. Evaluation of noncardiac chest pain in Indian setting—can we reduce the investigation burden? Indian J Gastroenterol. 2015;34:266–7.PubMed
73.
Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med. 2006;166:965–71.PubMed
74.
Fan W, Hou Y, Sun X, et al. Effects of high-fat, standard, and functional food meals on esophageal and gastric pH in patients with gastroesophageal reflux disease and healthy subjects. J Dig Dis. 2018;19:664–73.PubMed
75.
Wu KL, Kuo CM, Yao CC, et al. The effect of dietary carbohydrate on gastroesophageal reflux disease. J Formos Med Assoc. 2018;117:973–8.PubMed
76.
Shapiro M, Green C, Bautista JM, et al. Assessment of dietary nutrients that influence perception of intra-oesophageal acid reflux events in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2007;25:93–101.PubMed
77.
Dent J, Vakil N, Jones R, et al. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. Gut. 2010;59:714–21.PubMed
78.
Hunt R, Armstrong D, Katelaris P, et al. World Gastroenterology Organisation global guidelines: GERD global perspective on gastroesophageal reflux disease. J Clin Gastroenterol. 2017;51:467–78.PubMed
79.
Gasiorowska A, Fass R. The proton pump inhibitor (PPI) test in GERD: does it still have a role? J Clin Gastroenterol. 2008;42:867–74.PubMed
80.
Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172–80.PubMedPubMedCentral
81.
Dent J. Endoscopic grading of reflux oesophagitis: the past, present and future. Best Pract Res Clin Gastroenterol. 2008;22:585–99.PubMed
82.
Rosaida MS, Goh KL. Gastro-oesophageal reflux disease, reflux oesophagitis and non-erosive reflux disease in a multiracial Asian population: a prospective, endoscopy based study. Eur J Gastroenterol Hepatol. 2004;16:495–501.PubMed
83.
Dutta AK, Chacko A, Balekuduru A, Sahu MK, Gangadharan SK. High prevalence of significant endoscopic findings in patients with uninvestigated typical reflux symptoms. Am J Gastroenterol. 2011;106:1172–3.PubMed
84.
Savarino E, Gemignani L, Pohl D, Zentilin P, Dulbecco P, Assandri L. Oesophageal motility and bolus transit abnormalities increase in parallel with the severity of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2011;34:476–86.PubMed
85.
Kahrilas PJ, McColl K, Fox M, et al. The acid pocket: a target for treatment in reflux disease? Am J Gastroenterol. 2013;108:1058–64.PubMed
86.
Vaezi MF, Sifrim D. Assessing old and new diagnostic tests for gastroesophageal reflux disease. Gastroenterology. 2018;154:289–301.PubMed
87.
Dhawan PS, Alvares JF, Vora IM, et al. Prevalence of short segments of specialized columnar epithelium in distal esophagus: association with gastroesophageal reflux. Indian J Gastroenterol. 2001;20:144–7.PubMed
88.
Mathew P, Joshi AS, Shukla A, Bhatia SJ. Risk factors for Barrett's esophagus in Indian patients with gastroesophageal reflux disease. J Gastroenterol Hepatol. 2011;26:1151-6.PubMed
89.
Kao SS, Chen WC, Hsu PI, et al. The frequencies of gastroesophageal and extragastroesophageal symptoms in patients with mild erosive esophagitis, severe erosive esophagitis, and Barrett’s esophagus in Taiwan. Gastroenterol Res Pract. 2013;2013:480325.PubMedPubMedCentral
90.
Johnsson F, Joelsson B, Gudmundsson K, Greiff L. Symptoms and endoscopic findings in the diagnosis of gastroesophageal reflux disease. Scand J Gastroenterol. 1987;22:714–8.PubMed
91.
Gyawali CP, Kahrilas PJ, Savarino E, et al. Modern diagnosis of GERD: the Lyon consensus. Gut. 2018;67:1351–62.PubMed
92.
Roman S, Gyawali CP, Savarino E, et al. GERD consensus group. Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: update of the Porto consensus and recommendations from an international consensus group. Neurogastroenterol Motil. 2017;29:1–15.PubMed
93.
Madan K, Ahuja V, Gupta SD, Bal C, Kapoor A, Sharma MP. Impact of 24-h esophageal pH monitoring on the diagnosis of gastroesophageal reflux disease: defining the gold standard. J Gastroenterol Hepatol. 2005;20:30–7.PubMed
94.
Prakash C, Clouse RE. Value of extended recording time with wireless pH monitoring in evaluating gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2005;3:329–34.PubMed
95.
Wong WM, Bautista J, Dekel R, et al. Feasibility and tolerability of transnasal/per-oral placement of the wireless pH capsule vs. traditional 24-h oesophageal pH monitoring—a randomized trial. Aliment Pharmacol Ther. 2005;21:155–63.PubMed
96.
Karyampudi A, Ghoshal UC, Singh R, Verma A, Misra A, Saraswat VA. Esophageal acidification during nocturnal acid-breakthrough with ilaprazole versus omeprazole in gastroesophageal reflux disease. J Neurogastroenterol Motil. 2017;23:208–17.PubMedPubMedCentral
97.
Weigt J, Kandulski A, Büsch F, Malfertheiner P. Nocturnal gastric acid breakthrough is not associated with night-time gastroesophageal reflux in GERD patients. Dig Dis. 2009;27:68–73.PubMed
98.
Jain M, Srinivas M, Bawane P, Venkataraman J. Basal lower esophageal sphincter pressure in gastroesophageal reflux disease: an ignored metric in high-resolution esophageal manometry. Indian J Gastroenterol. 2018;37:446–51.PubMed
99.
Patti MG, Diener U, Tamburini A, Molena D, Way LW. Role of esophageal function tests in diagnosis of gastroesophageal reflux disease. Dig Dis Sci. 2001;46:597–602.PubMed
100.
Spechler SJ, Souza RF, Rosenberg SJ, Ruben RA, Goyal RK. Heartburn in patients with achalasia. Gut. 1995;37:305–8.PubMedPubMedCentral
101.
Chourasia D, Misra A, Tripathi S, Krishnani N, Ghoshal UC. Patients with Helicobacter pylori infection have less severe gastroesophageal reflux disease: a study using endoscopy, 24-hour gastric and esophageal pH metry. Indian J Gastroenterol. 2011;30:12–21.PubMed
102.
Pandit BB, Lahoti M, Amarapurkar AD, Kamath R, Naik AS, Bhatia SJ. Relationship between Helicobacter pylori and gastro-esophageal reflux disease. Indian J Gastroenterol. 2003;22 Suppl 1:A11.
103.
Saleh CM, Smout AJ, Bredenoord AJ. The diagnosis of gastro-esophageal reflux disease cannot be made with barium esophagograms. Neurogastroenterol Motil. 2015;27:195–200.PubMed
104.
Rey JW, Deris N, Marquardt JU, et al. High-definition endoscopy with iScan and Lugol's solution for the detection of inflammation in patients with nonerosive reflux disease: histologic evaluation in comparison with a control group. Dis Esophagus. 2016;29:185-91.PubMed
105.
Miyasaka M, Hirakawa M, Nakamura K, et al. The endoscopic diagnosis of nonerosive reflux disease using flexible spectral imaging color enhancement image: a feasibility trial. Dis Esophagus. 2011;24:395-400.PubMed
106.
Fock KM, Teo EK, Ang TL, et al. The utility of narrow band imaging in improving the endoscopic diagnosis of gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2009;7:54–9.PubMed
107.
Sharma P, Wani S, Bansal A, et al. A feasibility trial of narrow band imaging endoscopy in patients with gastroesophageal reflux disease. Gastroenterology. 2007;133:454–64.PubMed
108.
Chu CL, Zhen YB, Lv GP, et al. Microalterations of esophagus in patients with non-erosive reflux disease: in-vivo diagnosis by confocal laser endomicroscopy and its relationship with gastroesophageal reflux. Am J Gastroenterol. 2012;107:864–74.PubMed
109.
Smeets FG, Keszthelyi D, Bouvy ND, Masclee AA, Conchillo JM. Does measurement of esophagogastric junction distensibility by EndoFLIP predict therapy-responsiveness to endoluminal fundoplication in patients with gastroesophageal reflux disease? J Neurogastroenterol Motil. 2015;21:255–64.PubMedPubMedCentral
110.
Chen JW, Rubenstein JH. Esophagogastric junction distensibility assessed using the functional lumen imaging probe. World J Gastroenterol. 2017;23:1289–97.PubMedPubMedCentral
111.
Price SF, Smithson KW, Castell DO. Food sensitivity in reflux esophagitis. Gastroenterology. 1978;75:240–3.PubMed
112.
Boekema PJ, Samsom M, Smout AJ. Effect of coffee on gastro-oesophageal reflux in patients with reflux disease and healthy controls. Eur J Gastroenterol Hepatol. 1999;11:1271–6.PubMed
113.
Wang J-H, Luo J-Y, Dong L, Gong J, Tong M. Epidemiology of gastroesophageal reflux disease: a general population-based study in Xi’an of northwest China. World J Gastroenterol. 2004;10:1647–51.PubMedPubMedCentral
114.
Stanghellini V. Relationship between upper gastrointestinal symptoms and lifestyle, psychosocial factors and comorbidity in the general population: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl. 1999;231:29–37.PubMed
115.
Cohen S, Booth GH. Gastric acid secretion and lower-esophageal-sphincter pressure in response to coffee and caffeine. N Engl J Med. 1975;293:897–9.PubMed
116.
Kahrilas PJ, Gupta RR. The effect of cigarette smoking on salivation and esophageal acid clearance. J Lab Clin Med. 1989;114:431–8.PubMed
117.
Watanabe Y, Fujiwara Y, Shiba M, et al. Cigarette smoking and alcohol consumption associated with gastro-oesophageal reflux disease in Japanese men. Scand J Gastroenterol. 2003;38:807–11.PubMed
118.
Nilsson M, Johnsen R, Ye W, Hveem K, Lagergren J. Lifestyle related risk factors in the aetiology of gastro-oesophageal reflux. Gut. 2004;53:1730–5.PubMedPubMedCentral
119.
Schindlbeck NE, Heinrich C, Dendorfer A, Pace F, Müller-Lissner SA. Influence of smoking and esophageal intubation on esophageal pH-metry. Gastroenterology. 1987;92:1994–7.PubMed
120.
Waring JP, Eastwood TF, Austin JM, Sanowski RA. The immediate effects of cessation of cigarette smoking on gastroesophageal reflux. Am J Gastroenterol. 1989;84:1076–8.PubMed
121.
Kadakia SC, Kikendall JW, Maydonovitch C, Johnson LF. Effect of cigarette smoking on gastroesophageal reflux measured by 24-h ambulatory esophageal pH monitoring. Am J Gastroenterol. 1995;90:1785–90.PubMed
122.
Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Tobacco smoking cessation and improved gastroesophageal reflux: a prospective population-based cohort study: the HUNT study. Am J Gastroenterol. 2014;109:171–7.PubMed
123.
Bujanda L. The effects of alcohol consumption upon the gastrointestinal tract. Am J Gastroenterol. 2000;95:3374–82.PubMed
124.
125.
Ness-Jensen E, Hveem K, El-Serag H, Lagergren J. Lifestyle intervention in gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2016;14:175–82.PubMed
126.
Jacobson BC, Somers SC, Fuchs CS, Kelly CP, Camargo CA. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med. 2006;354:2340–8.PubMedPubMedCentral
127.
Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Weight loss and reduction in gastroesophageal reflux. A prospective population-based cohort study: the HUNT study. Am J Gastroenterol. 2013;108:376–82.PubMed
128.
Austin GL, Thiny MT, Westman EC, Yancy WS, Shaheen NJ. A very low-carbohydrate diet improves gastroesophageal reflux and its symptoms. Dig Dis Sci. 2006;51:1307–12.PubMed
129.
Fraser-Moodie CA, Norton B, Gornall C, Magnago S, Weale AR, Holmes GK. Weight loss has an independent beneficial effect on symptoms of gastro-oesophageal reflux in patients who are overweight. Scand J Gastroenterol. 1999;34:337–40.PubMed
130.
Mathus-Vliegen EM, Tygat GN. Gastro-oesophageal reflux in obese subjects: influence of overweight, weight loss and chronic gastric balloon distension. Scand J Gastroenterol. 2002;37:1246–52.PubMed
131.
Mathus-Vliegen LM, Tytgat GN. Twenty-four-hour pH measurements in morbid obesity: effects of massive overweight, weight loss and gastric distension. Eur J Gastroenterol Hepatol. 1996;8:635–40.PubMed
132.
Mathus-Vliegen EM, van Weeren M, van Eerten PV. Los function and obesity: the impact of untreated obesity, weight loss, and chronic gastric balloon distension. Digestion. 2003;68:161–8.PubMed
133.
Singh M, Lee J, Gupta N, et al. Weight loss can lead to resolution of gastroesophageal reflux disease symptoms: a prospective intervention trial. Obesity (Silver Spring). 2013;21:284–90.
134.
Sharma A, Aggarwal S, Ahuja V, Bal C. Evaluation of gastroesophageal reflux before and after sleeve gastrectomy using symptom scoring, scintigraphy, and endoscopy. Surg Obes Relat Dis. 2014;10:600–5.PubMed
135.
Stanciu C, Bennett JR. Effects of posture on gastro-oesophageal reflux. Digestion. 1977;15:104–9.PubMed
136.
Piesman M, Hwang I, Maydonovitch C, Wong RK. Nocturnal reflux episodes following the administration of a standardized meal. Does timing matter? Am J Gastroenterol. 2007;102:2128–34.PubMed
137.
Lanzon-Miller S, Pounder RE, McIsaac RL, Wood JR. The timing of the evening meal affects the pattern of 24-hour intragastric acidity. Aliment Pharmacol Ther. 1990;4:547–53.PubMed
138.
Duroux P, Bauerfeind P, Emde C, Koelz HR, Blum AL. Early dinner reduces nocturnal gastric acidity. Gut. 1989;30:1063–7.PubMedPubMedCentral
139.
Orr WC, Harnish MJ. Sleep-related gastro-oesophageal reflux: provocation with a late evening meal and treatment with acid suppression. Aliment Pharmacol Ther. 1998;12:1033–8.PubMed
140.
Tran T, Lowry AM, El-Serag HB. Meta-analysis: the efficacy of over-the-counter gastro-oesophageal reflux disease therapies. Aliment Pharmacol Ther. 2007;25:143–53.PubMed
141.
Surdea-Blaga T, Băncilă I, Dobru D, et al. Mucosal protective compounds in the treatment of gastroesophageal reflux disease. A position paper based on evidence of the Romanian Society of Neurogastroenterology. J Gastrointestin Liver Dis. 2016;25:537–46.PubMed
142.
Savarino E, Zentilin P, Marabotto E, et al. A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD). Expert Opin Pharmacother. 2017;18:1333–43.PubMed
143.
Simon B, Ravelli GP, Goffin H. Sucralfate gel versus placebo in patients with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1996;10:441–6.PubMed
144.
Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology. 2000;118 2 Suppl 1:S9–31.PubMed
145.
Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;5:CD002095.
146.
Gyawali CP, Fass R. Management of gastroesophageal reflux disease. Gastroenterology. 2018;154:302–18.PubMed
147.
Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol. 2011;106:1419–25.PubMed
148.
Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med. 2004;140:518–27.PubMed
149.
Weijenborg PW, Cremonini F, Smout AJ, Bredenoord AJ. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil. 2012;24:747–57.PubMed
150.
Bhatia S, Shukla A, Johnson D. An expert review and recommendations on the rational use of proton pump inhibitors: Indian perspective. J Assoc Physicians India. 2019;67:88-96.
151.
Zhang J-X, Ji M-Y, Song J, et al. Proton pump inhibitor for non-erosive reflux disease: a meta-analysis. World J Gastroenterol. 2013;19:8408–19.PubMedPubMedCentral
152.
Zhang H, Yang Z, Ni Z, Shi Y. A meta-analysis and systematic review of the efficacy of twice daily PPIs versus once daily for treatment of gastroesophageal reflux disease. Gastroenterol Res Pract. 2017;2017:9865963.PubMedPubMedCentral
153.
Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798–810.PubMed
154.
155.
Delchier JC, Cohen G, Humphries TJ. Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease. Scand J Gastroenterol. 2000;35:1245–50.PubMed
156.
Kinoshita Y, Hongo M, Japan TWICE Study Group. Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study. Am J Gastroenterol. 2012;107:522–30.PubMed
157.
Schindlbeck NE, Klauser AG, Berghammer G, Londong W, Müller-Lissner SA. Three year follow up of patients with gastrooesophageal reflux disease. Gut. 1992;33:1016–9.PubMedPubMedCentral
158.
Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology. 2001;121:1095–100.PubMed
159.
Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis—a placebo-controlled randomized trial. Aliment Pharmacol Ther. 1999;13:907–14.PubMed
160.
Zacny J, Zamakhshary M, Sketris I, Veldhuyzen van Zanten S. Systematic review: The efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients. Aliment Pharmacol Ther. 2005;21:1299–312.PubMed
161.
Pace F, Tonini M, Pallotta S, Molteni P, Porro GB. Systematic review: Maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken “on-demand.”. Aliment Pharmacol Ther. 2007;26:195–204.PubMed
162.
Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev. 2005 Apr 18;2:CD003245.
163.
Inadomi JM, McIntyre L, Bernard L, Fendrick AM. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol. 2003;98:1940–4.PubMed
164.
Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 1995;333:1106–10.PubMed
165.
Gough AL, Long RG, Cooper BT, Fosters CS, Garrett AD, Langworthy CH. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther. 1996;10:529–39.PubMed
166.
Mine S, Iida T, Tabata T, Kishikawa H, Tanaka Y. Management of symptoms in step-down therapy of gastroesophageal reflux disease. J Gastroenterol Hepatol. 2005;20:1365–70.PubMed
167.
Boghossian TA, Rashid FJ, Thompson W, et al. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Database Syst Rev. 2017;3:CD011969.PubMed
168.
Jaspersen D, Schwacha H, Schorr W, Brennenstuhl M, Raschka C, Hammar CH. Omeprazole in the treatment of patients with complicated gastro-oesophageal reflux disease. J Gastroenterol Hepatol. 1996;11:900–2.PubMed
169.
Swarbrick ET, Gough AL, Foster CS, Christian J, Garrett AD, Langworthy CH. Prevention of recurrence of oesophageal stricture, a comparison of lansoprazole and high-dose ranitidine. Eur J Gastroenterol Hepatol. 1996;8:431–8.PubMed
170.
Smith PM, Kerr GD, Cockel R, et al. A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Restore Invest Group. Gastroenterology. 1994;107:1312–8.PubMed
171.
Kuo B, Castell DO. Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol. 1996;91:1532–8.PubMed
172.
Xue S, Katz PO, Banerjee P, Tutuian R, Castell DO. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther. 2001;15:1351–6.PubMed
173.
Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol. 1998;93:763–7.PubMed
174.
Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology. 1998;115:1335–9.PubMed
175.
Mainie I, Tutuian R, Castell DO. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough. J Clin Gastroenterol. 2008;42:676–9.PubMed
176.
Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology. 2002;122:625–32.PubMed
177.
Ours TM, Fackler WK, Richter JE, Vaezi MF. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol. 2003;98:545–50.PubMed
178.
Dean BB, Gano AD, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2:656–64.PubMed
179.
Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2006;23:1473–7.PubMed
180.
Fass R, Sontag SJ, Traxler B, Sostek M. Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial. Clin Gastroenterol Hepatol. 2006;4:50–6.PubMed
181.
Khan M, Santana J, Donnellan C, Preston C, Moayyedi P. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev. 2007;(2):CD003244.
182.
Madan K, Ahuja V, Kashyap PC, Sharma MP. Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. Dis Esophagus. 2004;17:274–8.PubMed
183.
Ren L-H, Chen W-X, Qian L-J, Li S, Gu M, Shi R-H. Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis. World J Gastroenterol. 2014;20:2412–9.PubMedPubMedCentral
184.
Kessing BF, Smout AJ, Bennink RJ, Kraaijpoel N, Oors JM, Bredenoord AJ. Prucalopride decreases esophageal acid exposure and accelerates gastric emptying in healthy subjects. Neurogastroenterol Motil. 2014;26:1079–86.PubMed
185.
Futagami S, Iwakiri K, Shindo T, et al. The prokinetic effect of mosapride citrate combined with omeprazole therapy improves clinical symptoms and gastric emptying in PPI-resistant NERD patients with delayed gastric emptying. J Gastroenterol. 2010;45:413–21.PubMed
186.
Kamiya T, Adachi H, Hirako M, et al. Impaired gastric motility and its relationship to reflux symptoms in patients with nonerosive gastroesophageal reflux disease. J Gastroenterol. 2009;44:183–9.PubMed
187.
Giudicessi JR, Ackerman MJ, Camilleri M. Cardiovascular safety of prokinetic agents: a focus on drug-induced arrhythmias. Neurogastroenterol Motil. 2018;30:e13302.PubMedPubMedCentral
188.
Li S, Shi S, Chen F, Lin J. The effects of baclofen for the treatment of gastroesophageal reflux disease: a meta-analysis of randomized controlled trials. Gastroenterol Res Pract. 2014;2014:307805.PubMedPubMedCentral
189.
Kahrilas PJ, Boeckxstaens G, Smout AJ. Management of the patient with incomplete response to PPI therapy. Best Pract Res Clin Gastroenterol. 2013;27:401–14.PubMedPubMedCentral
190.
Vashani K, Murugesh M, Hattiangadi G, et al. Effectiveness of voice therapy in reflux-related voice disorders. Dis Esophagus. 2010;23:27-32.PubMed
191.
Gopal B, Singhal P, Gaur SN. Gastroesophageal reflux disease in bronchial asthma and the response to omeprazole. Asian Pac J Allergy Immunol. 2005;23:29–34.
192.
Kahrilas PJ, Hughes N, Howden CW. Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. Gut. 2011;60:1473–8.PubMed
193.
Irwin RS, Zawacki JK, Wilson MM, French CT, Callery MP. Chronic cough due to gastroesophageal reflux disease: failure to resolve despite total/near-total elimination of esophageal acid. Chest. 2002;121:1132–40.PubMed
194.
Chang AB, Lasserson TJ, Gaffney J, Connor FL, Garske LA. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database Syst Rev. 2011;1:CD004823.
195.
Gopal B, Singhal P, Gaur SN. Gastroesophageal reflux disease in bronchial asthma and the response to omeprazole. Asian Pac J Allergy Immunol. 2005;23:29–34.PubMed
196.
Harding SM, Richter JE, Guzzo MR, Schan CA, Alexander RW, Bradley LA. Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome. Am J Med. 1996;100:395–405.PubMed
197.
Kiljander TO, Salomaa ER, Hietanen EK, Terho EO. Gastroesophageal reflux in asthmatics: a double-blind, placebo-controlled crossover study with omeprazole. Chest. 1999;116:1257–64.PubMed
198.
Meier JH, McNally PR, Punja M, et al. Does omeprazole (Prilosec) improve respiratory function in asthmatics with gastroesophageal reflux? A double-blind, placebo-controlled crossover study. Dig Dis Sci. 1994;39:2127–33.PubMed
199.
American Lung Association Asthma Clinical Research Centers, Mastronarde JG, Anthonisen NR, et al. Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med. 2009;360:1487–99.PubMedCentral
200.
Littner MR, Leung FW, Ballard ED, Huang B, Samra NK, Lansoprazole Asthma Study Group. Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. Chest. 2005;128:1128–35.PubMed
201.
Gralnek IM, Dulai GS, Fennerty MB, Spiegel BM. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol. 2006;4:1452–8.PubMed
202.
Chen L, Chen Y, Li B. The efficacy and safety of proton-pump inhibitors in treating patients with non-erosive reflux disease: a network meta-analysis. Sci Rep. 2016;6:321–26.
203.
204.
Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association technical review on the management of Barrett’s esophagus. Gastroenterology. 2011;140:e18–52.PubMed
205.
Johnson DA, Katz PO, Armstrong D, et al. The safety of appropriate use of over-the-counter proton pump inhibitors: an evidence-based review and Delphi consensus. Drugs. 2017;77:547–61.PubMedPubMedCentral
206.
Scarpignato C, Gatta L, Zullo A, Blandizzi C, SIF-AIGO-FIMMG Group, Italian Society of Pharmacology, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases—a position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14:179.
207.
Kia L, Kahrilas PJ. Therapy: risks associated with chronic PPI use—signal or noise? Nat Rev Gastroenterol Hepatol. 2016;13:253–4.PubMed
208.
Moayyedi P, Eikelboom J, Bosch J, Dyal L, Connolly S, Yusuf S. Adverse events related to proton pump inhibitor therapy. Results of a randomized trial of pantoprazole versus placebo with 53,152 patient years of follow-up. Gastroenterology. 2019;156:S173–4.
209.
Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria. Gastroenterology. 2006;131:1392–9.PubMed
210.
Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association technical review on the management of Barrett’s esophagus. Gastroenterology. 2011;140:e18–52.PubMed
211.
Wang KK, Sampliner RE, Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol. 2008;103:788–97.PubMed
212.
Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63:7–42.PubMed
213.
Lee YC, Cook MB, Bhatia S, et al. Interobserver reliability in the endoscopic diagnosis and grading of Barrett’s esophagus: an Asian multi-national study. Endoscopy. 2010;42:699–704.PubMedPubMedCentral
214.
Ishimura N, Amano Y, Sollano JD, et al. Questionnaire-based survey conducted in 2011 concerning endoscopic management of Barrett’s esophagus in East Asian countries. Digestion. 2012;86:136–46.PubMed
215.
Aida J, Vieth M, Ell C, et al. Palisade vessels as a new histologic marker of esophageal origin in ER specimens from columnar-lined esophagus. Am J Surg Pathol. 2011;35:1140–5.PubMed
216.
Kandiah K, Chedgy FJQ, Subramaniam S, et al. International development and validation of a classification system for the identification of Barrett’s neoplasia using acetic acid chromoendoscopy: the Portsmouth Acetic Acid Classification (PREDICT). Gut. 2018;67:2085–91.PubMed
217.
Sharma P, Bergman J, Goda K, et al. Development and validation of a classification system to identify high-grade dysplasia and esophageal adenocarcinoma in Barrett’s esophagus using narrow-band imaging. Gastroenterology. 2016;150:591–8.PubMed
218.
Smith RR, Hamilton SR, Boitnott JK, et al. The spectrum of carcinoma arising in Barrett’s esophagus. A clinicopathologic study of 26 patients. Am J Surg Pathol. 1984;8:563–73.PubMed
219.
Skinner DB, Walther BC, Riddell RH, et al. Barrett’s esophagus. Comparison of benign and malignant cases. Ann Surg. 1983;198:554–65.PubMedPubMedCentral
220.
Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103:1049–57.PubMedPubMedCentral
221.
Goda K, Singh R, Oda I, et al. Current status of endoscopic diagnosis and treatment of superficial Barrett’s adenocarcinoma in Asia-Pacific region. Dig Endosc. 2013;25 Suppl 2:146–50.PubMed
222.
Fock KM, Talley NJ, Fass R, et al. Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol. 2008;23:8–22.PubMed
223.
Harrison R, Perry I, Haddadin W, et al. Detection of intestinal metaplasia in Barrett’s esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am J Gastroenterol. 2007;102:1154–61.PubMed
224.
Kelty CJ, Gough MD, Van Wyk Q, et al. Barrett’s oesophagus: intestinal metaplasia is not essential for cancer risk. Scand J Gastroenterol. 2007;42:1271–4.PubMed
225.
Gatenby PA, Ramus JR, Caygill CP, et al. Relevance of the detection of intestinal metaplasia in non-dysplastic columnar-lined oesophagus. Scand J Gastroenterol. 2008;43:524–30.PubMed
226.
Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001;32:368–78.PubMed
227.
Kerkhof M, van Dekken H, Steyerberg EW, et al. Grading of dysplasia in Barrett’s oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology. 2007;50:920–7.PubMed
228.
Curvers WL, ten Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105:1523–30.PubMed
229.
Duits LC, Phoa KN, Curvers WL, et al. Barrett’s oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel. Gut. 2015;64:700–6.PubMed
230.
Alikhan M, Rex D, Khan A, et al. Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest Endosc. 1999;50:23–6.PubMed
231.
Quante M, Graham TA, Jansen M. Insights into the pathophysiology of esophageal adenocarcinoma. Gastroenterology. 2018;154:406–20.PubMed
232.
Epari K, Cade R. Oesophagectomy for tumours and dysplasia of the oesophagus and gastro-oesophageal junction. ANZ J Surg. 2009;79:251–7.PubMed
233.
Qiao Y, Hyder A, Bae SJ, et al. Surveillance in patients with Barrett’s esophagus for early detection of esophageal adenocarcinoma: a systematic review and meta-analysis. Clin Transl Gastroenterol. 2015;6:e131.PubMedPubMedCentral
234.
Cherian JV, Sivaraman R, Muthusamy AK, Jayanthi V. Carcinoma of the esophagus in Tamil Nadu (South India): 16-year trends from a tertiary center. J Gastrointestin Liver Dis. 2007;16:245–9.PubMed
235.
Streitz JM Jr, Andrews CW Jr, Ellis FH Jr. Endoscopic surveillance of Barrett’s esophagus. Does it help? J Thorac Cardiovasc Surg. 1993;105:383–7.PubMed
236.
Peters JH, Clark GW, Ireland AP, et al. Outcome of adenocarcinoma arising in Barrett’s esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg. 1994;108:813–21.PubMed
237.
van Sandick JW, van Lanschot JJ, Kuiken BW, et al. Impact of endoscopic biopsy surveillance of Barrett’s oesophagus on pathological stage and clinical outcome of Barrett’s carcinoma. Gut. 1998;43:216–22.PubMedPubMedCentral
238.
Corley DA, Levin TR, Habel LA, et al. Surveillance and survival in Barrett’s adenocarcinomas: a population-based study. Gastroenterology. 2002;122:633–40.PubMed
239.
Cooper GS, Yuan Z, Chak A, et al. Association of pre-diagnosis endoscopy with stage and survival in adenocarcinoma of the esophagus and gastric cardia. Cancer. 2002;95:32–8.PubMed
240.
Fountoulakis A, Zafirellis KD, Dolan K, et al. Effect of surveillance of Barrett’s oesophagus on the clinical outcome of oesophageal cancer. Br J Surg. 2004;91:997–1003.PubMed
241.
Rubenstein JH, Sonnenberg A, Davis J, et al. Effect of a prior endoscopy on outcomes of esophageal adenocarcinoma among United States veterans. Gastrointest Endosc. 2008;68:849–55.PubMedPubMedCentral
242.
Corley DA, Mehtani K, Quesenberry C, et al. Impact of endoscopic surveillance on mortality from Barrett’s esophagus-associated esophageal adenocarcinomas. Gastroenterology. 2013;145:312–9.PubMed
243.
Gordon LG, Mayne GC, Hirst NG, et al. Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett’s esophagus. Gastrointest Endosc. 2014;79:242–56.PubMed
244.
Visrodia K, Iyer PG, Schleck CD, Zinsmeister AR, Katzka DA. Yield of repeat endoscopy in Barrett’s esophagus with no dysplasia and low-grade dysplasia: a population-based study. Dig Dis Sci. 2016;61:158–67.PubMed
245.
Rodriguez S, Mattek N, Lieberman D, Fennerty B, Eisen G. Barrett’s esophagus on repeat endoscopy: should we look more than once? Am J Gastroenterol. 2008;103:1892–7.PubMedPubMedCentral
246.
Hanna S, Rastogi A, Weston AP, et al. Detection of Barrett’s esophagus after endoscopic healing of erosive esophagitis. Am J Gastroenterol. 2006;101:1416–20.PubMed
247.
Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002;97:575–83.PubMed
248.
Richter JE, Kahrilas PJ, Sontag SJ, Kovacs TO, Huang B, Pencyla JL. Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. Am J Gastroenterol. 2001;96:3089–98.PubMed
249.
Palmer ED. The hiatus herniaesophagitis-esophageal stricture complex: twenty-year prospective study. Am J Med. 1968;44:566–79.PubMed
250.
Rejeb BM, Bouche O, Zeitoun P. Study of 47 consecutive patients with peptic esophageal stricture compared with 3880 cases of reflux esophagitis. Dig Dis Sci. 1992;37:733–6.PubMed
251.
Marks RD, Richter JE, Rizzo J, et al. Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology. 1994;106:907–15.PubMed
252.
Fass R, Cahn F, Scotti DJ, Gregory DA. Systematic review and meta-analysis of controlled and prospective cohort efficacy studies of endoscopic radiofrequency for treatment of gastroesophageal reflux disease. Surg Endos. 2017;31:4865–82.PubMed
253.
Kalapala R, Shah H, Nabi Z, Darisetty S, Talukdar R, Nageshwar Reddy D. Treatment of gastroesophageal reflux disease using radiofrequency ablation (Stretta procedure): an interim analysis of a randomized trial. Indian J Gastroenterol. 2017;36:337–42.PubMed
254.
Koch OO, Kaindlstorfer A, Antoniou SA, Spaun G, Pointner R, Swanstrom LL. Subjective and objective data on esophageal manometry and impedance pH monitoring 1 year after endoscopic full-thickness plication for the treatment of GERD by using multiple plication implants. Gastrointest Endosc. 2013;77:7–14.PubMed
255.
Zaninotto G, Attwood SE. Surgical management of refractory gastro-oesophageal reflux. Br J Surg. 2010;97:139–40.PubMed
256.
Jiang Y, Cui W-X, Wang Y, et al. Antireflux surgery vs medical treatment for gastroesophageal reflux disease: a meta-analysis. World J Meta-Anal. 2015;3:284–94.
257.
The SAGES Guidelines Committee, Stefanidis D, Hope WW, Kohn GP, Reardon PR, Richardson WS, et al. Guidelines for surgical treatment of gastroesophageal reflux disease. Surg Endosc. 2010;24:2647–69.
258.
Peters MJ, Mukhtar A, Yunus RM, et al. Meta-analysis of randomized clinical trials comparing open and laparoscopic anti-reflux surgery. Am J Gastroenterol. 2009;104:1548–61.PubMed
259.
Singhal V, Khaitan L. Preoperative evaluation of gastroesophageal reflux disease. Surg Clin North Am. 2015;95:615–27.PubMed
260.
Nagpal AP, Soni H, Haribhakti S. Is oesophageal manometry a must before laparoscopic fundoplication? Analysis of 46 consecutive patients treated without preoperative manometry. J Minim Access Surg. 2010;6:66–9.PubMedPubMedCentral
261.
Nagpal AP, Soni H, Haribhakti SP. Retrospective evaluation of patients of gastroesophageal reflux disease treated with laparoscopic Nissen’s fundoplication. J Minim Access Surg. 2010;6:42–5.PubMedPubMedCentral
262.
Herregods TV, Troelstra M, Weijenborg PW, et al. Patients with refractory reflux symptoms often do not have GERD. Neurogastroenterol Motil. 2015;27:1267–73.PubMed
263.
Khajanchee YS, Dunst CM, Swanstrom LL. Outcomes of Nissen fundoplication in patients with gastroesophageal reflux disease and delayed gastric emptying. Arch Surg. 2009;144:823–8.PubMed
264.
Noar MD, Noar E. Gastroparesis associated with gastroesophageal reflux disease and corresponding reflux symptoms may be corrected by radiofrequency ablation of the cardia and esophagogastric junction. Surg Endosc. 2008;22:2440–4.PubMed
Metadaten
Titel
Indian consensus on gastroesophageal reflux disease in adults: A position statement of the Indian Society of Gastroenterology
verfasst von
Shobna J. Bhatia
Govind K. Makharia
Philip Abraham
Naresh Bhat
Ajay Kumar
D. Nageshwar Reddy
Uday C. Ghoshal
Vineet Ahuja
G. Venkat Rao
Krishnadas Devadas
Amit K. Dutta
Abhinav Jain
Saurabh Kedia
Rohit Dama
Rakesh Kalapala
Jose Filipe Alvares
Sunil Dadhich
Vinod Kumar Dixit
Mahesh Kumar Goenka
B. D. Goswami
Sanjeev K. Issar
Venkatakrishnan Leelakrishnan
Mohandas K. Mallath
Philip Mathew
Praveen Mathew
Subhashchandra Nandwani
Cannanore Ganesh Pai
Lorance Peter
A. V. Siva Prasad
Devinder Singh
Jaswinder Singh Sodhi
Randhir Sud
Jayanthi Venkataraman
Vandana Midha
Amol Bapaye
Usha Dutta
Ajay K. Jain
Rakesh Kochhar
Amarender S. Puri
Shivram Prasad Singh
Lalit Shimpi
Ajit Sood
Rajkumar T. Wadhwa
Publikationsdatum
05.12.2019
Verlag
Springer India
Erschienen in
Indian Journal of Gastroenterology / Ausgabe 5/2019
Print ISSN: 0254-8860
Elektronische ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-019-00979-y

Weitere Artikel der Ausgabe 5/2019

Indian Journal of Gastroenterology 5/2019 Zur Ausgabe

Original Article

Reliability of indocyanine green retention and clearance rates at 15 minutes calculated by dye-dilution cardiac output flowmetry in comparison to blood sampling in patients undergoing hepatic resection

Original Article

Prevalence of thyroid autoimmunity in first-degree relatives of patients with celiac disease

Original Article

Multimodality management, recurrence patterns, and long-term outcome of gastroenteropancreatic neuroendocrine neoplasms: Progress over 17 years

Original Article

Microstructural diversity of gallstones revealed by spectral microanalyses and their association with hepatic parameters

Image

Mesh migration after hiatal hernia repair

Review Article

All that a physician should know about FODMAPs

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise